Brought to you by 
Biogen pays Forward Pharma non-refundable $1.25bn for IP rights
15 Sep 2017
Executive Summary
Under terms of a binding agreement, Biogen Inc. is paying $1.25bn in exchange for an irrevocable license to all intellectual property owned by Forward Pharma AS in the US. The license term is perpetual and exclusive but subject to certain conditions which, if not satisfied, can change to co-exclusive in which case Biogen would pay a 1% royalty starting January 1, 2023 until the earlier of the expiration, unenforceability, or invalidation of the patents in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com